

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

Recombinant Anti-CD8 alpha antibody [EPR22483-288]

RRID:AB_3068617

Type: Antibody

Proper Citation

Abcam Cat# ab245118, RRID:AB_3068617

Antibody Information

URL: http://antibodyregistry.org/AB_3068617

Proper Citation: Abcam Cat# ab245118, RRID:AB_3068617

Target Antigen: CD8 alpha

Host Organism: Rabbit

Clonality: recombinant monoclonal

Comments: Applications: IHC-P, Flow Cyt, IP

Antibody Name: Recombinant Anti-CD8 alpha antibody [EPR22483-288]

Description: This recombinant monoclonal targets CD8 alpha

Target Organism: human

Clone ID: EPR22483-288

Antibody ID: AB_3068617

Vendor: Abcam

Catalog Number: ab245118

Record Creation Time: 20231110T031029+0000

Record Last Update: 20260831T230217+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-CD8 alpha antibody [EPR22483-288].

No alerts have been found for Recombinant Anti-CD8 alpha antibody [EPR22483-288].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kirschstein E, et al. (2026) Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer. *Cancer cell*, 44(5), 1080.

Yao L, et al. (2026) Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy. *Cell reports. Medicine*, 102928.

Zhang T, et al. (2026) Proteogenomic characterization delineates clinically relevant subtypes of advanced differentiated thyroid cancer. *Cell reports. Medicine*, 7(3), 102661.

Chi H, et al. (2025) SEMA3G-NRP1 Signaling Functions as an Immune Checkpoint That Enables Tumor Immune Evasion by Impairing T-cell Cytotoxicity. *Cancer research*, 85(5), 912.

Gu J, et al. (2025) Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity. *Cell*.

Chen D, et al. (2025) Single-cell profiles delineate immune cell remodeling and enhanced tumor-fibroblast interaction of hepatoblastoma after chemotherapy. *Cell reports. Medicine*, 102401.

Chen Z, et al. (2024) YTHDF2-mediated circYAP1 drives immune escape and cancer progression through activating YAP1/TCF4-PD-L1 axis. *iScience*, 27(2), 108779.

Chen S, et al. (2024) Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance. *NPJ precision oncology*, 8(1), 159.

Wang X, et al. (2024) *Fusobacterium nucleatum* facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. *Cancer cell*, 42(10), 1729.

Deng S, et al. (2024) ITPRIPL1 binds CD3? to impede T cell activation and enable tumor immune evasion. *Cell*, 187(9), 2305.